View Past PerformanceTELCON RF PHARMACEUTICAL バランスシートの健全性財務の健全性 基準チェック /66TELCON RF PHARMACEUTICALの総株主資本は₩97.4B 、総負債は₩38.0Bで、負債比率は39%となります。総資産と総負債はそれぞれ₩150.4Bと₩53.0Bです。 TELCON RF PHARMACEUTICALの EBIT は₩795.0Mで、利息カバレッジ比率0.2です。現金および短期投資は₩30.8Bです。主要情報39.01%負債資本比率₩38.00b負債インタレスト・カバレッジ・レシオ0.2x現金₩30.84bエクイティ₩97.42b負債合計₩52.97b総資産₩150.39b財務の健全性に関する最新情報分析記事 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...すべての更新を表示Recent updatesNew Risk • Jun 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 90% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (90% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩24.7b market cap, or US$16.3m).New Risk • May 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩14.7b market cap, or US$9.77m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • Apr 18TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 3 billion in funding from Nuon Co., Ltd.On April 17, 2026. TELCON RF PHARMACEUTICAL. Inc. announced that it has closed the transaction.New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$19.1m).お知らせ • Apr 09TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 3 billion in funding from Nuon Co., Ltd.TELCON RF PHARMACEUTICAL. Inc. has announced to issue 3,000,000 common stock at a price of KRW 1000 per share for gross proceeds of KRW 3,000,000,000 on April 7, 2026. The transaction include investor participation from Nuon Co., Ltd. The transaction has been approved by board of directors. The transaction is expected to close on April 17, 2026. All the securities issued pursuant to the offering is subject to hold period of one year.お知らせ • Mar 06TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, baegam-myeon, cheoin-gu, gyeonggi-do, yongin South Korea分析記事 • Feb 05Some Shareholders Feeling Restless Over TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 0.9x in the Electronic industry in Korea, you could be...分析記事 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Sep 11More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders won't be pleased to see that the share price has had a...お知らせ • Aug 13TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion.TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,822,520 Price\Range: KRW 3835 Discount Per Security: KRW 95.875 Transaction Features: Rights Offering分析記事 • Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With RevenuesTELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shares have continued their recent momentum with a 35% gain in the...New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩39.7b market cap, or US$28.9m).お知らせ • Apr 22+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 12 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On April 22, 2025, TELCON RF PHARMACEUTICAL. Inc. closed the transaction,分析記事 • Mar 24TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too SoonThere wouldn't be many who think TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of...お知らせ • Mar 12TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, cheoin-gu, gyeonggi-do, yongin South KoreaNew Risk • Dec 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩7.19b (US$5.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩7.19b market cap, or US$5.02m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding).お知らせ • Nov 12ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion.ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion on November 11, 2024. The consideration consist of issue of 2.42 million common stock of ABION Inc. (KOSDAQ:A203400). The expected completion of the transaction is December 16, 2024.分析記事 • Oct 23TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in the Electronic industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...分析記事 • Sep 06TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A CompanyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • May 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (₩84.7b market cap, or US$62.4m).Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩736, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.お知らせ • Apr 20+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.TELCON RF PHARMACEUTICAL. Inc. announced a private placement to issue Series 20 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 22,000,000,000 on April 18, 2024. The transaction will include participation from new investors Sangsangin Savings Bank for KRW 12,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 10,000,000,000. The transaction has been approved by the shareholders of the company, restricted to a hold period and is expected to close on April 19, 2024. The bonds are 100% convertible into 29,891,304 shares at a fixed conversion price of KRW 736 from April 19, 2025 to March 19, 2027. The bonds bear 2% coupon rate, 5% maturity rate and matures on April 19, 2027.分析記事 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.分析記事 • Mar 13TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than ExpectedTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of 2.4x may not look like an...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩818, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 86% over the past three years.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩994, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (₩109.3b market cap, or US$83.3m).Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩977, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 84% over the past three years.分析記事 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Feb 24New 90-day low: ₩4,890The company is down 23% from its price of ₩6,360 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.分析記事 • Feb 03Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders might be concerned after seeing the share price drop 20...Is New 90 Day High Low • Jan 28New 90-day low: ₩5,160The company is down 14% from its price of ₩6,010 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.Is New 90 Day High Low • Jan 11New 90-day low: ₩5,490The company is down 31% from its price of ₩7,920 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 37% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: ₩5,810The company is down 42% from its price of ₩9,990 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 15% over the same period.お知らせ • Nov 05Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.Telcon RF Pharmaceutical Inc. (KOSDAQ:A200230) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 4,290,000,000, series 17 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 22,000,000,000, and series 18 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 14,360,000,000, for aggregate gross proceeds of KRW 40,650,000,000 on November 3, 2020. The transaction will include participation from returning investor Hanil Vacuum Co., Ltd. (KOSDAQ:A123840) for the series 16 and 17 bonds and Evercore Investment Holdings for series 18 bonds. All the bonds carry a coupon rate of 3% and yield to maturity of 5%, and will mature on November 3, 2023. The series 16 bonds are fully convertible into 636,781 shares at a conversion price of KRW 6,737 per share which represents 0.74% stake in the company; the series 17 bonds are fully convertible into 3,265,548 shares at a conversion price of KRW 6,737 per share which represents 3.68% stake; and the series 18 bonds are fully convertible into 2,131,512 shares at a conversion price of KRW 6,737 per share which represents 2.43% stake. The conversion for all the bonds period starts from November 3, 2021 to October 3, 2023. The bonds have a hold period of one year. The transaction has been approved by the board of the directors of the company.お知らせ • Sep 29TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) announced a private placement to issue series 15 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 30,000,000,000 on September 28, 2020. The transaction will include participation from returning investor Emmaus Life Sciences, Inc. (OTCPK:EMMA). The bonds carry a coupon rate and interest rate to maturity of 2.1%, and will mature on October 16, 2030. Interest to be paid every three months deferred to the interest payment date every three months from the day after the issue of the bond to the due date of repayment of the principal. The bonds are 100% convertible into 3,249,566 shares at a conversion price of KRW 9,232 per share which represents 3.80% stake in the company. The conversion period starts from October 16, 2021 and end on September 16, 2030. The bonds have a hold period of one year. The transaction is expected to close on October 16, 2020. The transaction has been approved by the board of the directors.財務状況分析短期負債: A200230の 短期資産 ( ₩63.8B ) が 短期負債 ( ₩51.5B ) を超えています。長期負債: A200230の短期資産 ( ₩63.8B ) が 長期負債 ( ₩1.5B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: A200230の 純負債対資本比率 ( 7.3% ) は 満足できる 水準であると考えられます。負債の削減: A200230の負債対資本比率は、過去 5 年間で91.9%から39%に減少しました。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 利益は出ていないものの、 A200230は現在のプラスの フリーキャッシュフロー レベルを維持すれば、3 年以上は十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: A200230は利益は出ていませんが、フリーキャッシュフローがプラスで年間2.1 % 減少しているにもかかわらず、3 年以上は十分なキャッシュランウェイがあります。健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/03 20:43終値2026/06/02 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TELCON RF PHARMACEUTICAL. Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Yang Ju ParkDaishin Securities Co. Ltd.
分析記事 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
New Risk • Jun 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 90% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (90% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩24.7b market cap, or US$16.3m).
New Risk • May 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩14.7b (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩14.7b market cap, or US$9.77m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • Apr 18TELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 3 billion in funding from Nuon Co., Ltd.On April 17, 2026. TELCON RF PHARMACEUTICAL. Inc. announced that it has closed the transaction.
New Risk • Apr 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$19.1m).
お知らせ • Apr 09TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 3 billion in funding from Nuon Co., Ltd.TELCON RF PHARMACEUTICAL. Inc. has announced to issue 3,000,000 common stock at a price of KRW 1000 per share for gross proceeds of KRW 3,000,000,000 on April 7, 2026. The transaction include investor participation from Nuon Co., Ltd. The transaction has been approved by board of directors. The transaction is expected to close on April 17, 2026. All the securities issued pursuant to the offering is subject to hold period of one year.
お知らせ • Mar 06TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 27, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, baegam-myeon, cheoin-gu, gyeonggi-do, yongin South Korea
分析記事 • Feb 05Some Shareholders Feeling Restless Over TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) P/S RatioWith a median price-to-sales (or "P/S") ratio of close to 0.9x in the Electronic industry in Korea, you could be...
分析記事 • Dec 02Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Sep 11More Unpleasant Surprises Could Be In Store For TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares After Tumbling 30%TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders won't be pleased to see that the share price has had a...
お知らせ • Aug 13TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion.TELCON RF PHARMACEUTICAL. Inc. has completed a Follow-on Equity Offering in the amount of KRW 41.504364 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 10,822,520 Price\Range: KRW 3835 Discount Per Security: KRW 95.875 Transaction Features: Rights Offering
分析記事 • Jul 22TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) 35% Price Boost Is Out Of Tune With RevenuesTELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shares have continued their recent momentum with a 35% gain in the...
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩39.7b market cap, or US$28.9m).
お知らせ • Apr 22+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it has received KRW 12 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On April 22, 2025, TELCON RF PHARMACEUTICAL. Inc. closed the transaction,
分析記事 • Mar 24TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Shares May Have Run Too Fast Too SoonThere wouldn't be many who think TELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of...
お知らせ • Mar 12TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025TELCON RF PHARMACEUTICAL. Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 205, goan-ro 51beon-gil, cheoin-gu, gyeonggi-do, yongin South Korea
New Risk • Dec 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩7.19b (US$5.02m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₩7.19b market cap, or US$5.02m). Minor Risk Shareholders have been diluted in the past year (7.5% increase in shares outstanding).
お知らせ • Nov 12ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion.ABION Inc. (KOSDAQ:A203400) agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) for KRW 20.1 billion on November 11, 2024. The consideration consist of issue of 2.42 million common stock of ABION Inc. (KOSDAQ:A203400). The expected completion of the transaction is December 16, 2024.
分析記事 • Oct 23TELCON RF PHARMACEUTICAL. Inc.'s (KOSDAQ:200230) Popularity With Investors Is Under Threat From OverpricingWhen close to half the companies in the Electronic industry in Korea have price-to-sales ratios (or "P/S") below 0.7x...
分析記事 • Sep 06TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Could Be At Risk Of Shrinking As A CompanyWhen it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • May 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (₩84.7b market cap, or US$62.4m).
Valuation Update With 7 Day Price Move • May 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩736, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.
お知らせ • Apr 20+ 1 more updateTELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 22 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.TELCON RF PHARMACEUTICAL. Inc. announced a private placement to issue Series 20 Bearer Interest Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 22,000,000,000 on April 18, 2024. The transaction will include participation from new investors Sangsangin Savings Bank for KRW 12,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 10,000,000,000. The transaction has been approved by the shareholders of the company, restricted to a hold period and is expected to close on April 19, 2024. The bonds are 100% convertible into 29,891,304 shares at a fixed conversion price of KRW 736 from April 19, 2025 to March 19, 2027. The bonds bear 2% coupon rate, 5% maturity rate and matures on April 19, 2027.
分析記事 • Mar 26Investors Shouldn't Be Too Comfortable With TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) EarningsTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) stock was strong after they recently reported robust earnings...
Reported Earnings • Mar 23Full year 2023 earnings released: EPS: ₩124 (vs ₩397 loss in FY 2022)Full year 2023 results: EPS: ₩124 (up from ₩397 loss in FY 2022). Revenue: ₩36.3b (up 31% from FY 2022). Net income: ₩13.9b (up ₩56.0b from FY 2022). Profit margin: 38% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
分析記事 • Mar 13TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230) Investors Are Less Pessimistic Than ExpectedTELCON RF PHARMACEUTICAL. Inc.'s ( KOSDAQ:200230 ) price-to-sales (or "P/S") ratio of 2.4x may not look like an...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩818, the stock trades at a trailing P/E ratio of 9.1x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 86% over the past three years.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩994, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 17x in the Electronic industry in South Korea. Total loss to shareholders of 85% over the past three years.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (₩109.3b market cap, or US$83.3m).
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 42%After last week's 42% share price gain to ₩977, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 15x in the Electronic industry in South Korea. Total loss to shareholders of 84% over the past three years.
分析記事 • Apr 05Is TELCON RF PHARMACEUTICAL (KOSDAQ:200230) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Feb 24New 90-day low: ₩4,890The company is down 23% from its price of ₩6,360 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 29% over the same period.
分析記事 • Feb 03Did Business Growth Power TELCON RF PHARMACEUTICAL's (KOSDAQ:200230) Share Price Gain of 218%?TELCON RF PHARMACEUTICAL. Inc. ( KOSDAQ:200230 ) shareholders might be concerned after seeing the share price drop 20...
Is New 90 Day High Low • Jan 28New 90-day low: ₩5,160The company is down 14% from its price of ₩6,010 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 56% over the same period.
Is New 90 Day High Low • Jan 11New 90-day low: ₩5,490The company is down 31% from its price of ₩7,920 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 37% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: ₩5,810The company is down 42% from its price of ₩9,990 on 24 September 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Electronic industry, which is up 15% over the same period.
お知らせ • Nov 05Telcon RF Pharmaceutical Inc. announced that it has received KRW 40.65 billion in funding from Hanil Vacuum Co., Ltd.Telcon RF Pharmaceutical Inc. (KOSDAQ:A200230) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 4,290,000,000, series 17 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 22,000,000,000, and series 18 unregistered coupon non-guaranteed private convertible bonds for gross proceeds of KRW 14,360,000,000, for aggregate gross proceeds of KRW 40,650,000,000 on November 3, 2020. The transaction will include participation from returning investor Hanil Vacuum Co., Ltd. (KOSDAQ:A123840) for the series 16 and 17 bonds and Evercore Investment Holdings for series 18 bonds. All the bonds carry a coupon rate of 3% and yield to maturity of 5%, and will mature on November 3, 2023. The series 16 bonds are fully convertible into 636,781 shares at a conversion price of KRW 6,737 per share which represents 0.74% stake in the company; the series 17 bonds are fully convertible into 3,265,548 shares at a conversion price of KRW 6,737 per share which represents 3.68% stake; and the series 18 bonds are fully convertible into 2,131,512 shares at a conversion price of KRW 6,737 per share which represents 2.43% stake. The conversion for all the bonds period starts from November 3, 2021 to October 3, 2023. The bonds have a hold period of one year. The transaction has been approved by the board of the directors of the company.
お知らせ • Sep 29TELCON RF PHARMACEUTICAL. Inc. announced that it expects to receive KRW 30 billion in funding from Emmaus Life Sciences, Inc.TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:A200230) announced a private placement to issue series 15 non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 30,000,000,000 on September 28, 2020. The transaction will include participation from returning investor Emmaus Life Sciences, Inc. (OTCPK:EMMA). The bonds carry a coupon rate and interest rate to maturity of 2.1%, and will mature on October 16, 2030. Interest to be paid every three months deferred to the interest payment date every three months from the day after the issue of the bond to the due date of repayment of the principal. The bonds are 100% convertible into 3,249,566 shares at a conversion price of KRW 9,232 per share which represents 3.80% stake in the company. The conversion period starts from October 16, 2021 and end on September 16, 2030. The bonds have a hold period of one year. The transaction is expected to close on October 16, 2020. The transaction has been approved by the board of the directors.